No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
UNCY Unicycive Therapeutics
- 0.6458
- -0.0045-0.69%
Close Jun 18 16:00 ET
- 0.6740
- +0.0282+4.37%
Post 18:49 ET
24.29MMarket Cap-701P/E (TTM)
0.6919High0.6249Low505.46KVolume0.6496Open0.6503Pre Close337.99KTurnover3.42%Turnover RatioLossP/E (Static)37.61MShares1.818052wk High-0.99P/B9.54MFloat Cap0.470052wk Low--Dividend TTM14.78MShs Float8.7300Historical High--Div YieldTTM10.30%Amplitude0.4004Historical Low0.6680Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
Unicycive Therapeutics: A Buy Rating on the Horizon With Promising Drug Developments and Market Potential
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersReshape Lifesciences (NASDAQ:RSLS) shares rose 88.9% to $0.39 during Tuesday's after-market session. The market value of their outstanding shares is at $9.2 million. Dermata Therapeutics (NASDA
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference
LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company or
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersSharps Technology (NASDAQ:STSS) stock increased by 56.5% to $0.4 during Wednesday's after-market session. The market value of their outstanding shares is at $6.3 million. Geovax Labs (NASDAQ:GO
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)
Comments
$Unicycive Therapeutics(UNCY.US$
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress
Unicycive Therapeutics presented data on its two product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the European Renal Association Congress on May 28, 2024. OLC demonstrated a three-fold greater phosphate lowering capacity compared to tenapanor in a preclinical model of CKD, showing its potential as a t...
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress
Unicycive Therapeutics presented data on its two product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the European Renal Association Congress on May 28, 2024. OLC demonstrated a three-fold greater phosphate lowering capacity compared to tenapanor in a preclinical model of CKD, showing its potential as a t...
OLC represents a next-generation leap in the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).
Unicycive Therapeutics, Inc., a clinical-stage biotechnology firm dedicated to improving the lives of patients with kidney disease, recently made strides in showcasing its innovative capabilities at the National Kidney Foundation (NKF) Spring Clinical Meeting. The company's lead product candidate, oxylanthanum carbonate ...
Unicycive Therapeutics, Inc., a clinical-stage biotechnology firm dedicated to improving the lives of patients with kidney disease, recently made strides in showcasing its innovative capabilities at the National Kidney Foundation (NKF) Spring Clinical Meeting. The company's lead product candidate, oxylanthanum carbonate ...
$Unicycive Therapeutics(UNCY.US$
NEWS
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting
Unicycive Therapeutics presented two posters on their lead product, oxylanthanum carbonate (OLC), at the National Kidney Foundation Spring Clinical Meeting. The key points include:
1. OLC shows bioequivalence to lanthanum carbonate, with similar outcomes in mean change in urinary phosphate excretion and no serious adv...
NEWS
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting
Unicycive Therapeutics presented two posters on their lead product, oxylanthanum carbonate (OLC), at the National Kidney Foundation Spring Clinical Meeting. The key points include:
1. OLC shows bioequivalence to lanthanum carbonate, with similar outcomes in mean change in urinary phosphate excretion and no serious adv...
Unicycive Therapeutics Inc. Announces $50 Million Private Placement: Here's What It Means for You.
Unicycive Therapeutics Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company, announced on March 14, 2024, that it has secured a $50 million private placement from undisclosed investors. This news could have significant implications for the company's ongoing research and development efforts, and it may affect future inves...
Unicycive Therapeutics Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company, announced on March 14, 2024, that it has secured a $50 million private placement from undisclosed investors. This news could have significant implications for the company's ongoing research and development efforts, and it may affect future inves...
$Unicycive Therapeutics(UNCY.US$ Went higher than when i posted FDA orphan drug status 3 days ago! Again trust the process! Hehehe
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg